위식도 접합부 선암 치료제 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 16.1%로 성장할 전망이며, 81억 5,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 정밀 종양학에 대한 주목, 집학적 치료 접근 증가, 리퀴드 바이옵시 사용 확대, 저침습 치료로의 전환, 면역 종양학 치료의 채용 증가에 의해 초래됩니다. 주요 동향으로는 임상 진료에 있어서 차세대 시퀀서 통합, 표적 방사선 요법 혁신, 분자 이미징에서의 진보, 치료 계획에 있어서 인공지능 용도, 수술 기법의 개선 등을 들 수 있습니다.
비만률의 상승은 위식도 접합부 선암(GEJA) 치료제 시장의 성장을 가속할 것으로 예측됩니다. 체지방의 과잉 축적을 특징으로 하는 비만증은, 식생활의 혼란, 앉기 쉬운 라이프 스타일, 운동 부족, 가공 식품이나 고칼로리 식품 섭취 등의 요인에 의해 증가하고 있습니다. GEJA 치료제는 염증, 대사 교란, 호르몬 밸런스 교란 등 체중 증가의 원인이 되는 근본적인 기전에 대처하는데 중요한 역할을 하고 있습니다. 예를 들어 2024년 3월 스위스에 본부를 둔 정부 간 기관인 세계보건기구(WHO)는 전 세계 약 8명 중 1명이 비만으로 고민하고 있다고 보고했습니다. 이 중에는 과체중으로 분류되는 성인이 25억 명 포함되어 있고, 그 중 8억 9,000만 명이 비만과 공존하고 있습니다. 성인 중 43%가 과체중이고 16%가 비만으로 분류돼 있습니다. 게다가 5세 미만의 과체중 어린이의 수는 3,700만 명에 달했습니다. 따라서 비만율의 증가가 GEJA 치료제 시장의 확대에 박차를 가하고 있습니다.
GEJA 치료제 시장의 주요 기업은 치료 효과를 높이고 환자의 결과를 개선하고 기존 치료에 대한 내성에 대처하기 위한 혁신적인 병용 요법의 개발에 주력하고 있습니다. 병용요법은 약제나 치료법 등 2개 이상의 치료약을 이용해 유효성을 향상시키고 질환의 여러 측면을 동시에 표적으로 하는 것입니다. 예를 들면, 2024년 10월, 일본의 제약회사인 아스텔라스 제약은 플루오로피리미딘 및 플래티넘 제제를 포함한 화학요법과 병용하는 졸베툭시맙-clzb의 미국 식품의약국(FDA)의 승인을 취득했습니다. 졸베툭시맙-clzb는 위암이나 GEJ암에서 고발현하는 클로딘 18.2를 특이적으로 표적으로 하는 퍼스트 인 클래스의 모노클로날 항체로 치료 정확도 및 치료 효과를 향상시킵니다. CLDN18.2를 발현하고 있는 암세포에 선택적으로 결합함으로써 치료효과를 최적화하면서 건강조직에 대한 손상을 최소화하는 표적 접근이 가능해집니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 위식도 접합부 선암 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 위식도 접합부 선암 치료제 시장 : 성장률 분석
- 세계의 위식도 접합부 선암 치료제 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 위식도 접합부 선암 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 위식도 접합부 선암 치료제 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 위식도 접합부 선암 치료제 시장 : 약물별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 트라스투주맙
- 람실마맙
- 세계의 위식도 접합부 선암 치료제 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 내시경 검사
- X선
- 컴퓨터 단층 촬영(CT) 스캔
- 양전자 방출 단층 촬영(PET) 스캔
- 세계의 위식도 접합부 선암 치료제 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 식도 절제 수술
- 식도 확장
- 화학요법
- 표적요법
- 세계의 위식도 접합부 선암 치료제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 위식도 접합부 선암 치료제 시장 : 트라스투주맙 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 단제요법
- 화학요법과의 병용요법
- 세계의 위식도 접합부 선암 치료제 시장 : 람실맙 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 단제요법
- 파클리탁셀과의 병용 요법
제7장 지역별 및 국가별 분석
- 세계의 위식도 접합부 선암 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 위식도 접합부 선암 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 위식도 접합부 선암 치료제 시장 : 경쟁 구도
- 위식도 접합부 선암 치료제 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- F Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
- AstraZeneca plc 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Company Limited
- Genentech Inc.
- Incyte Corporation
- Ono Pharmaceutical Co. Ltd.
- BeiGene Ltd.
- Zymeworks Inc.
- Zai Lab Limited
- ImmunoGen Inc.
- Elevar Therapeutics Inc.
- Mirati Therapeutics Inc.
- Shanghai Henlius Biotech Inc.
- Taiho Pharmaceutical Co. Ltd.
- LintonPharm Ltd.
- Celltrion Healthcare Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 위식도 접합부 선암 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
- 위식도 접합부 선암 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
- 위식도 접합부 선암 치료제 시장(2029년) : 성장 전략
제36장 부록
AJY
Gastroesophageal junction adenocarcinoma is a malignant tumor that forms at the junction of the esophagus and stomach, often linked to chronic acid reflux, obesity, and other risk factors. Its treatment options include targeted therapies, immunotherapy, chemotherapy, and surgical procedures designed to slow tumor progression, improve survival rates, and enhance patient outcomes.
The primary therapeutics for gastroesophageal junction adenocarcinoma include trastuzumab and ramucirumab. Trastuzumab is a targeted therapy drug used to treat HER2-positive gastroesophageal junction adenocarcinoma by blocking the HER2 protein, which contributes to cancer growth. Diagnosis is conducted through procedures such as endoscopy, X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan. Treatment approaches include esophagectomy surgery, esophageal dilation, chemotherapy, and targeted therapy. These therapeutics are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The gastroesophageal junction adenocarcinoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal junction adenocarcinoma therapeutics market statistics, including the gastroesophageal junction adenocarcinoma therapeutics industry global market size, regional shares, competitors with the gastroesophageal junction adenocarcinoma therapeutics market share, detailed gastroesophageal junction adenocarcinoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gastroesophageal junction adenocarcinoma therapeutics industry. This gastroesophageal junction adenocarcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gastroesophageal junction adenocarcinoma therapeutics market size has grown rapidly in recent years. It will grow from $3.85 billion in 2024 to $4.48 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period was driven by the rising prevalence of *Helicobacter pylori* infection, the increasing number of Barrett's esophagus cases, the expansion of screening programs, greater investment in research and development, and improved healthcare access.
The gastroesophageal junction adenocarcinoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $8.15 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The projected growth during the forecast period is driven by a focus on precision oncology, an increase in multidisciplinary treatment approaches, the expanding use of liquid biopsies, a shift toward minimally invasive procedures, and the rising adoption of immuno-oncology treatments. Key trends include the integration of next-generation sequencing in clinical practice, innovations in targeted radiation therapy, advancements in molecular imaging, the application of artificial intelligence in treatment planning, and improvements in surgical techniques.
The rising obesity rates are expected to drive the growth of the gastroesophageal junction adenocarcinoma (GEJA) therapeutics market. Obesity, a condition characterized by excessive body fat accumulation, is increasing due to factors such as poor dietary habits, sedentary lifestyles, lack of physical activity, and the consumption of processed and high-calorie foods. GEJA therapeutics play a crucial role in addressing the underlying mechanisms that contribute to weight gain, including inflammation, metabolic disruption, and hormonal imbalances, which can be exacerbated by the disease. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were struggling with obesity. This included 2.5 billion adults classified as overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the growing obesity rates are fueling the expansion of the GEJA therapeutics market.
Leading companies in the GEJA therapeutics market are focused on developing innovative combination therapies to enhance treatment efficacy, improve patient outcomes, and address resistance to existing treatments. Combination therapy involves using two or more therapeutic agents, such as drugs or treatment modalities, to improve effectiveness and target multiple aspects of a disease simultaneously. For example, in October 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for zolbetuximab-clzb in combination with fluoropyrimidine- and platinum-containing chemotherapy. Zolbetuximab-clzb is a first-in-class monoclonal antibody specifically targeting Claudin 18.2, a protein highly expressed in gastric and GEJ cancers, thereby improving treatment precision and effectiveness. By selectively binding to CLDN18.2-expressing cancer cells, this therapy enables a targeted approach, minimizing damage to healthy tissues while optimizing therapeutic outcomes.
In January 2023, Leap Therapeutics Inc., a US-based biotech company, acquired Flame Biosciences Inc. for $115 million. This acquisition strengthens Leap Therapeutics' oncology pipeline by integrating innovative cancer therapies developed by Flame Biosciences, expanding its portfolio of targeted treatments, and advancing research efforts to develop cutting-edge solutions for GEJA and other cancers. Flame Biosciences Inc., a US-based company, specializes in developing therapeutics for gastroesophageal junction adenocarcinoma, further enhancing Leap Therapeutics' capabilities in this market.
Major players in the gastroesophageal junction adenocarcinoma therapeutics market are Pfizer Inc., F Hoffmann-La Roche AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Genentech Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., Zymeworks Inc., Zai Lab Limited, ImmunoGen Inc., Elevar Therapeutics Inc., Mirati Therapeutics Inc., Shanghai Henlius Biotech Inc., Taiho Pharmaceutical Co. Ltd., LintonPharm Ltd., Celltrion Healthcare Co. Ltd.
North America was the largest region in the gastroesophageal junction adenocarcinoma therapeutics market in 2024. The regions covered in gastroesophageal junction adenocarcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gastroesophageal junction adenocarcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gastroesophageal junction adenocarcinoma therapeutics market includes revenues earned by entities by providing services such as radiation therapy, immunotherapy, surgical oncology, and palliative care and related products such as angiogenesis inhibitors, chemoradiation therapy, biosimilars, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastroesophageal junction adenocarcinoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastroesophageal junction adenocarcinoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroesophageal junction adenocarcinoma therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug: Trastuzumab; Ramucirumab
- 2) By Diagnosis: Endoscopy; X-ray; Computed Tomography (CT) Scan; Positron Emission Tomography (PET) Scan
- 3) By Treatment: Esophagectomy Surgery; Esophageal Dilation; Chemotherapy; Targeted Therapy
- 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
- Subsegments:
- 1) By Trastuzumab: Monotherapy; Combination Therapy With Chemotherapy
- 2) By Ramucirumab: Monotherapy; Combination Therapy With Paclitaxel
- Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche AG; Merck & Co. Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Characteristics
3. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Trends And Strategies
4. Gastroesophageal Junction Adenocarcinoma Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate Analysis
- 5.4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Total Addressable Market (TAM)
6. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Segmentation
- 6.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Trastuzumab
- Ramucirumab
- 6.2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Endoscopy
- X-ray
- Computed Tomography (CT) Scan
- Positron Emission Tomography (PET) Scan
- 6.3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Esophagectomy Surgery
- Esophageal Dilation
- Chemotherapy
- Targeted Therapy
- 6.4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- 6.5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Sub-Segmentation Of Trastuzumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monotherapy
- Combination Therapy With Chemotherapy
- 6.6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Sub-Segmentation Of Ramucirumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monotherapy
- Combination Therapy With Paclitaxel
7. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Regional And Country Analysis
- 7.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 8.1. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 9.1. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 9.2. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 10.1. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 11.1. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 11.2. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 12.1. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 13.1. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 14.1. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 14.2. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 15.1. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 15.2. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 16.1. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 17.1. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 18.1. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 19.1. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 20.1. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 21.1. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 21.2. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 22.1. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 23.1. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 23.2. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 24.1. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 24.2. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 25.1. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 25.2. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 26.1. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 26.2. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 27.1. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 28.1. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 28.2. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market
- 29.1. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
- 29.2. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Landscape
- 30.2. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Other Major And Innovative Companies
- 31.1. Teva Pharmaceutical Industries Ltd.
- 31.2. Daiichi Sankyo Company Limited
- 31.3. Genentech Inc.
- 31.4. Incyte Corporation
- 31.5. Ono Pharmaceutical Co. Ltd.
- 31.6. BeiGene Ltd.
- 31.7. Zymeworks Inc.
- 31.8. Zai Lab Limited
- 31.9. ImmunoGen Inc.
- 31.10. Elevar Therapeutics Inc.
- 31.11. Mirati Therapeutics Inc.
- 31.12. Shanghai Henlius Biotech Inc.
- 31.13. Taiho Pharmaceutical Co. Ltd.
- 31.14. LintonPharm Ltd.
- 31.15. Celltrion Healthcare Co. Ltd.
32. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gastroesophageal Junction Adenocarcinoma Therapeutics Market
34. Recent Developments In The Gastroesophageal Junction Adenocarcinoma Therapeutics Market
35. Gastroesophageal Junction Adenocarcinoma Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
